Vertex reaches long-term reimbursement agreement with ROI for Orkambi, Kalydeco and future CF medicines

Agreement provides access to Orkambi for people who have two copies of the F508del mutation and expands access to Kalydeco for all eligible patients.

“We are pleased that these additional Irish CF patients will finally join the thousands of others around the world who are already benefitting from Orkambi and Kalydeco,” said Simon Bedson, Senior Vice President and International General Manager at Vertex. “We thank the leaders in Ireland for working with us toward an innovative reimbursement agreement that provides access to these important medicines and also recognizes the need for Vertex’s continued investment in the research and development of new medicines for those people with CF, many of whom are still waiting for a treatment for the underlying cause of the disease.”

CF is a rare and life-shortening genetic disease caused by a defective or missing cystic fibrosis transmembrane conductance regulator (CFTR) protein resulting from a mutation in the CFTR gene. Orkambi and Kalydeco are the first two medicines that treat the underlying cause of CF. Ireland has the highest rate of CF in the world, with approximately one in 19 Irish people carrying a disease-causing mutation in one copy of the CFTR gene.

In addition to Ireland, Orkambi is available to all eligible patients in Austria, Denmark, France, Germany, Luxembourg and the US. People in 27 countries are benefitting from Kalydeco. Vertex remains actively involved in additional reimbursement discussions globally, with the goal of making these transformative medicines available to all eligible patients as soon as possible.